二甲双胍对卵巢癌总生存影响的SEER-Medicare分析
基于SEER-Medicare数据库2007至2011年首次诊断上皮性卵巢癌的2291例患者,其中180例(7.9%)使用二甲双胍。倾向性评分匹配后,二甲双胍使用与总生存无统计学显著关联(匹配队列HR 0.88,95%CI 0.66-1.17);探索性时变系数回归提示随访30个月后存活者中可能具保护效应(HR 0.37,95%CI 0.16-0.87)。
要点
- 全队列中二甲双胍使用与总生存无显著关联(HR 0.96,95%CI 0.75-1.23)。
- 匹配队列中二甲双胍使用与总生存无显著关联(HR 0.88,95%CI 0.66-1.17)。
- 探索性分析提示随访30个月后存活者中二甲双胍可能具保护效应(HR 0.37,95%CI 0.16-0.87)。
核心结论
- 在360例卵巢癌匹配队列中,二甲双胍使用与总生存无统计学显著关联,但探索性建模提示二甲双胍使用可能在特定亚组患者中具保护作用。
研究设计与样本
- 基于SEER-Medicare数据库的观察性研究,纳入2007至2011年首次诊断上皮性卵巢癌患者,最终2291例符合纳入标准。
- 使用Cox比例风险生存模型评估二甲双胍使用与否的总生存,并用倾向性评分匹配控制混杂。
- 采用离散时间生存分析合并逻辑回归评估剂量对生存的影响。
主要发现
- 2291例中180例(7.9%)曾使用二甲双胍,中位年龄73岁,83.5%为白人,74.1%接受初次手术治疗。
- 全队列中二甲双胍使用与总生存无显著关联(HR 0.96,95%CI 0.75-1.23)。
- 匹配样本队列中二甲双胍使用与总生存无显著关联(HR 0.88,95%CI 0.66-1.17)。
- 探索性时变系数回归提示随访30个月后存活者中二甲双胍具保护效应(HR 0.37,95%CI 0.16-0.87)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Determine whether metformin use is associated with improved survival in patients with ovarian, fallopian tube or primary peritoneal cancer. METHODS: All patients with a diagnosis of first epithelial ovarian cancer from 2007 to 2011 in the combined SEER-Medicare database were identified from the SEER registry primary site codes. Comorbidities, procedures and cancer treatment ICD-9 and HCPCS codes were used to search the Medicare claims files. Medication use was determined with National Drug Codes using the Medicare Part D event files. The primary outcome, overall survival, was assessed between metformin users and non-users using a Cox Proportional Hazards survival model. To control for confounding, metformin users were matched to non-metformin users using propensity scores. Effect of dosage on survival was assessed using discrete time survival analysis with pooled logistic regression (PLR). RESULTS: There were 2291 cases that met our inclusion criteria. Of these, 180 (7.9%) had been on metformin. The median age was 73years, with the majority of the population being White (83.5%) and treated with primary surgery (74.1%). Metformin use was not associated with overall survival in the entire cohort (HR 0.96, 95% CI 0.75-1.23) or in the matched sample cohort (HR 0.88, 95% CI 0.66-1.17). However, exploratory regression with time-varying coefficients suggests a protective metformin effect for women alive after 30months follow-up (HR=0.37, 95% 0.16-0.87). CONCLUSION: No statistically significant association was observed between metformin use and overall survival in a matched cohort of 360 ovarian cancer patients. However, exploratory modeling suggests metformin use may be protective in a certain subgroup of patients.
引用
- Garcia C, Yao A, Camacho F, et al. A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer. Gynecol Oncol. 2017. PMID: 28499649. doi:10.1016/j.ygyno.2017.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。